Comparative Pharmacology
Head-to-head clinical analysis: LANREOTIDE ACETATE versus MYCAPSSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANREOTIDE ACETATE versus MYCAPSSA.
LANREOTIDE ACETATE vs MYCAPSSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lanreotide is a synthetic octapeptide analog of somatostatin. It binds predominantly to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. It also reduces secretion of gastrointestinal hormones such as serotonin and gastrin.
Somatostatin analogue that inhibits growth hormone (GH), insulin-like growth factor 1 (IGF-1), and glucagon secretion by binding to somatostatin receptors (subtypes 2 and 5 predominantly).
90 mg subcutaneously every 4 weeks
40 mg subcutaneously twice daily.
None Documented
None Documented
Terminal elimination half-life: 23-30 hours following subcutaneous administration; prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life is approximately 11-13 hours in healthy volunteers, allowing for twice-daily dosing. In patients with moderate hepatic impairment, half-life may be prolonged, necessitating dose adjustment.
Primarily renal (approximately 60-70% of dose excreted unchanged in urine), with biliary/fecal elimination accounting for about 30%.
Renal excretion accounts for approximately 50-60% of clearance, with the remainder primarily hepatic/biliary excretion (30-40%) and fecal elimination (10-20%). Unchanged drug in urine is minimal (<10%); most is excreted as metabolites.
Category C
Category C
Somatostatin Analog
Somatostatin Analog